Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain

Abstract

Objective: The treatment of iron deficiency (ID) with ferric carboxymaltose (FCM) improves the functional class and quality of life of chronic heart failure (CHF) patients with reduced left ventricular ejection fraction (LVEF), and reduces the rate of hospitalization due to worsening CHF. This study aims to evaluate the budget impact for the Spanish National Health System (SNHS) of treating ID in reduced LVEF CHF with FCM compared to non-iron treatment. Methods: We simulated a hypothetical cohort of 1000 CHF patients with ID and reduced LVEF based on the Spanish population characteristics. A decision-analytic model was also built using the data from the largest FCM clinical trial (CONFIRM-HF) that lasted for a year. We considered the use of healthcare resources from a national prospective study. A deterministic sensitivity analysis was carried out varying the corresponding baseline data by ±25%. Results: The cost of treating the simulated population with FCM was e2,570,914, while that of the non-iron treatment was e3,105,711, which corresponds to a cost saving of e534,797 per 1,000 patients in one year. Cost savings were mainly due to a decrease in the number of hospitalizations. All sensitivity analysis showed cost savings for the SNHS. Conclusions: FCM results in an annual cost saving of e534.80 per patient, and would thus be expected to reduce the economic burden of CHF in Spain.

Cost-Effectiveness and Budget Impact Analyses of Patient Blood Management in a Cardiovascular Surgery Department at Ankara Bilkent City Hospital in Turkey

“…In both this and a previous study [ 33 ], ferric carboxymaltose treatment was found to be cost saving. These results are similar to results reported for other countries such as France [ 53 , 54 ], Spain [ 55 ], Greece [ 56 ], and Germany [ 57 , 58 ].…”

Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation

“…This is consistent with other published budget impact studies, which have also shown either cost savings, or modest cost increases, associated with FCM therapy in HF patients across many European countries 12,20,28–30 . A Spanish budget impact study, using data from CONFIRM‐HF, reported an annual cost saving of €534.80 per patient with FCM treatment versus non‐iron treatment, driven by a decrease in hospitalizations 30 . Similarly, a French budget impact analysis extrapolating data from the CONFIRM‐HF trial demonstrated cumulative cost savings of €0.8 m with FCM compared to no treatment 12 .…”

“…Herein, we quantify the budget savings projected to be associated with the introduction of FCM in the eligible population, highlighting the health economic value of adherence to the 2021 ESC guidelines for HF management, in addition to the clinical benefits 1 . This is consistent with other published budget impact studies, which have also shown either cost savings, or modest cost increases, associated with FCM therapy in HF patients across many European countries 12,20,28–30 . A Spanish budget impact study, using data from CONFIRM‐HF, reported an annual cost saving of €534.80 per patient with FCM treatment versus non‐iron treatment, driven by a decrease in hospitalizations 30 .…”

“…12,20,28-30 A Spanish budget impact study, using data from CONFIRM-HF, reported an annual cost saving of €534.80 per patient with FCM treatment versus non-iron treatment, driven by a decrease in hospitalizations. 30 Similarly, a French budget impact analysis extrapolating data from the CONFIRM-HF trial demonstrated cumulative cost savings of €0.8 m with FCM compared to no treatment. 12 These savings were driven by reduced hospitalization costs, associated with worsening HF, and decreased follow-up costs.…”